Detalhe da pesquisa
1.
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Haematologica
; 104(8): 1565-1571, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30733271
2.
Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.
Cancer Res Commun
; 4(6): 1441-1453, 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38727208
3.
Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma.
Blood Adv
; 5(20): 4003-4016, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474469
4.
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma.
Clin Cancer Res
; 26(12): 2819-2826, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900279
5.
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors.
Clin Cancer Res
; 26(18): 4777-4784, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32616501
6.
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Clin Cancer Res
; 26(5): 1009-1016, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31831561
7.
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
Clin Cancer Res
; 24(10): 2285-2293, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29500276
8.
Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma.
Epigenetics
; 11(10): 709-720, 2016 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27646854
9.
Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.
PLoS One
; 11(8): e0162105, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27579489